標(biāo)題: Titlebook: Bisphosphonates in Clinical Oncology; The Development of P Beat Thürlimann Book 1999 Springer-Verlag Berlin · Heidelberg 1999 Metastatic Bo [打印本頁(yè)] 作者: 惡夢(mèng) 時(shí)間: 2025-3-21 18:14
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology影響因子(影響力)
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology被引頻次
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology被引頻次學(xué)科排名
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology年度引用
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology年度引用學(xué)科排名
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology讀者反饋
書(shū)目名稱(chēng)Bisphosphonates in Clinical Oncology讀者反饋學(xué)科排名
作者: 條約 時(shí)間: 2025-3-21 23:20
Pamidronate,onate might be affected by the rate of administration, a prospective pharmacokinetic study of pamidronate at three different infusion rates was started in the Department of Internal Medicine C, Kantonsspital St. Gallen KSSG, Switzerland and in the Centre Pluridisciplinaire d’Oncologie and the Depart作者: EPT 時(shí)間: 2025-3-22 00:47 作者: consent 時(shí)間: 2025-3-22 05:12 作者: 乏味 時(shí)間: 2025-3-22 11:43 作者: 障礙 時(shí)間: 2025-3-22 15:46
Torsionsschwingungen in Antriebssystemen,nt. Finally, a prospective, randomized, double-blind, placebo-controlled, three-arm, phase-III study of ibandronate has been conducted in patients with breast cancer and bone metastases (SG 143/94). No results are available to the public so far.作者: projectile 時(shí)間: 2025-3-22 17:49 作者: GUISE 時(shí)間: 2025-3-22 21:17
Pamidronate,ew medication and no chemotherapy was started for at least 72 hr prior to entry or at any time during the study. Median creatinine clearance was 66 ml/min (range 37–110 ml/min). Mean age was 63 years (range 28–78 years). Thirty-two of the 37 patients suffered from bone metastases of breast cancer. T作者: 帶來(lái)墨水 時(shí)間: 2025-3-23 05:08 作者: 商品 時(shí)間: 2025-3-23 09:20
Beat ThürlimannImportant pathophysiological background of bone complications.Treatment possibilities作者: Foam-Cells 時(shí)間: 2025-3-23 12:45
Recent Results in Cancer Researchhttp://image.papertrans.cn/b/image/188891.jpg作者: mendacity 時(shí)間: 2025-3-23 15:26
https://doi.org/10.1007/978-3-642-59845-6Metastatic Bone Disease; Palliation; Pamidronate; Vitamin D; bisphosphonates; breast cancer; hormones; inte作者: 只有 時(shí)間: 2025-3-23 21:15 作者: 無(wú)能的人 時(shí)間: 2025-3-24 01:03 作者: 萬(wàn)花筒 時(shí)間: 2025-3-24 05:12 作者: Tartar 時(shí)間: 2025-3-24 10:07 作者: 偽造者 時(shí)間: 2025-3-24 13:21
Bisphosphonates in Clinical Oncology978-3-642-59845-6Series ISSN 0080-0015 Series E-ISSN 2197-6767 作者: 壓碎 時(shí)間: 2025-3-24 17:28
,Einführung in die Linsentheorie (27–46),The pharmacological approach to disorders of bone remodeling is based mainly on drugs that inhibit osteoclastic bone resorption. Fewer advances have been made in the development of drugs to stimulate bone formation.作者: osteopath 時(shí)間: 2025-3-24 22:21
Pharmacological Treatment of Bone Disorders,The pharmacological approach to disorders of bone remodeling is based mainly on drugs that inhibit osteoclastic bone resorption. Fewer advances have been made in the development of drugs to stimulate bone formation.作者: Repatriate 時(shí)間: 2025-3-25 01:07 作者: GRIEF 時(shí)間: 2025-3-25 06:14 作者: 實(shí)施生效 時(shí)間: 2025-3-25 11:09
0080-0015 onate in certain indications are given and put in perspective. The author discusses patient management guidelines as well as pharmaco-economic aspects important for the readers.978-3-642-64148-0978-3-642-59845-6Series ISSN 0080-0015 Series E-ISSN 2197-6767 作者: medieval 時(shí)間: 2025-3-25 14:41
Book 1999opment of pamidronate to treat tumor-induced hypercalcemia and malignant osteolytic bone disease is demonstrated, as well as the results of pivotal studies. New important findings on how to best use pamidronate in certain indications are given and put in perspective. The author discusses patient man作者: BANAL 時(shí)間: 2025-3-25 15:57 作者: 性別 時(shí)間: 2025-3-25 22:54 作者: 6Applepolish 時(shí)間: 2025-3-26 02:22
Teacher Education and Pedagogy of Science: Review and Reflectionrialization and for building a nation with citizens having a scientific attitude and temper, true science education is a necessity. The contribution of science in the modernisation of our country was realised soon enough after independence. The first Prime Minister of India, Jawaharlal Nehru once st作者: 越自我 時(shí)間: 2025-3-26 06:30
Living reference work 20200th editionlitischen Kommunikation von Unternehmen und anderen Organisationen. . Die interdisziplin?re Herangehensweise des Handbuchs berücksichtigt zum einen Erkenntnisse und Forschungsergebnisse aus unterschiedlichen wissenschaftlichen Disziplinen wie z.B. der Kommunikationswissenschaft, der Politikwissensch作者: 作繭自縛 時(shí)間: 2025-3-26 11:58 作者: Agility 時(shí)間: 2025-3-26 14:52 作者: Indurate 時(shí)間: 2025-3-26 18:02
Say Aye to AI: Customer Acceptance and Intention to Use Service Robots in the Hospitality Industry,t are significantly related to acceptance of service robots, which in turn, positively related to intention to use them. Implications of the research findings are discussed to support the notion should the industry Say Aye to AI.作者: oxidant 時(shí)間: 2025-3-26 23:35 作者: Temporal-Lobe 時(shí)間: 2025-3-27 03:39
Pier Francesco Melani,Paolo Schito,Giacomo Persico a special case of the weights treated in this book. In many ways, this book is the culmination of 18 years of joint work on orthogonal polynomials, drawing inspiration from the works of many researchers in the very active field of orthogonal polynomials.978-1-4612-6563-4978-1-4613-0201-8Series ISSN 1613-5237 Series E-ISSN 2197-4152 作者: 野蠻 時(shí)間: 2025-3-27 06:15 作者: 思想 時(shí)間: 2025-3-27 09:46
https://doi.org/10.1007/978-3-86226-396-7ion. Under the Helsinki Criteria, nearly twice as many deaths are believed to stem from asbestos-induced lung cancer. Japan must establish a public social insurance-type framework for relief compensation. To offset current deficiencies, Japan must also move forward with litigation seeking civil dama作者: BRACE 時(shí)間: 2025-3-27 16:27 作者: 避開(kāi) 時(shí)間: 2025-3-27 20:03
